87 results
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
Ordinary shares | Treasury shares | Additional paid-in | Accumulated other comprehensive | Accumulated | Total shareholders’ | |||||||||||||||||||||||||||
Shares | Cost | Shares | Cost | capital | (loss)/income | deficit | equity | |||||||||||||||||||||||||
Balance, December 31, 2023 | 701,217,089 | $ | 2,775 | 923,400 | $ | (1,230) | $ | 486,107 | $ | (17,485) | $ | (419,630) | $ | 50,537 | ||||||||||||||||||
Net loss | (8,951) | (8,951) | ||||||||||||||||||||||||||||||
Foreign currency translation adjustments | (798) | (798) | ||||||||||||||||||||||||||||||
Share-based compensation | 2,050 | 2,050 | ||||||||||||||||||||||||||||||
Exercise of share options | 132,345 | — | (210,485) | 280 | (280) | — | ||||||||||||||||||||||||||
Delivery of shares on vesting of restricted stock units | (712,915) | 950 | (950) | — | ||||||||||||||||||||||||||||
Balance, March 31, 2024 | 701,349,434 | $ | 2,775 | — | $ | — | $ | 486,927 | $ | (18,283) | $ | (428,581) | $ | 42,838 | ||||||||||||||||||
Balance, December 31, 2022 | 624,928,519 | $ | 2,478 | 1,003,030 | $ | (1,335) | $ | 476,521 | $ | (21,687) | $ | (404,575) | $ | 51,402 | ||||||||||||||||||
Net loss | (12,076) | (12,076) | ||||||||||||||||||||||||||||||
Foreign currency translation adjustments | 2,278 | 2,278 | ||||||||||||||||||||||||||||||
Extinguishment and reissuance of convertible loan note | 1,161 | 1,161 | ||||||||||||||||||||||||||||||
Share-based compensation | 1,635 | 1,635 | ||||||||||||||||||||||||||||||
Balance, March 31, 2023 | 624,928,519 | $ | 2,478 | 1,003,030 | $ | (1,335) | $ | 479,317 | $ | (19,409) | $ | (416,651) | $ | 44,400 |
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
Three months ended March 31, | ||||||||
2024 | 2023 | |||||||
($'000) | ($'000) | |||||||
Cash paid for amounts included in the measurement of lease liabilities: | ||||||||
Operating cash flows from operating leases | $ | 194 | $ | 153 |
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
March 31, | December 31, | |||||||
2024 | 2023 | |||||||
($'000) | ($'000) | |||||||
Social security and other taxes | $ | 391 | $ | 280 | ||||
Deferred consideration liability | 290 | 711 | ||||||
Other current liabilities | 37 | 30 | ||||||
Total | $ | 718 | $ | 1,021 |
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
March 31, | December 31, | |||||||
2024 | 2023 | |||||||
Expected volatility (%) | 90 | 102 | ||||||
Risk-free interest rate (%) | 3.80 | 3.36 | ||||||
Expected life of warrants (years) | 3.9 | 5.2 | ||||||
Market price of ADS ($) | 3.41 | 2.31 | ||||||
Model used | Black-Scholes | Black-Scholes |
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
Number of RSUs (ADSs) | Weighted Average Grant Date Fair Value ($) | Aggregate intrinsic value ($'000) | ||||||||||
At December 31, 2023 | 489,225 | 1.03 | 1,130 | |||||||||
Granted | 204,914 | 3.36 | — | |||||||||
Vested | (142,583) | 1.01 | 481 | |||||||||
Forfeited | (23,533) | 1.36 | — | |||||||||
At March 31, 2024 | 528,023 | 1.93 | 1,801 |
10-Q
slqx32
15 May 24
Quarterly report
4:19pm
10-Q
gnnqyte5
15 May 24
Quarterly report
4:19pm
10-Q
5yf2xdui3
15 May 24
Quarterly report
4:19pm
10-Q
hk16udr
15 May 24
Quarterly report
4:19pm
10-Q
cr1 djtigy1y1
15 May 24
Quarterly report
4:19pm
10-Q
zcn3kog
15 May 24
Quarterly report
4:19pm
10-Q
o4o e6lzaqa
15 May 24
Quarterly report
4:19pm
10-Q
hfye83p
15 May 24
Quarterly report
4:19pm
10-Q
tfikr h8tlm22sge9qh
15 May 24
Quarterly report
4:19pm
10-Q
1cd wokeno
15 May 24
Quarterly report
4:19pm
10-Q
hc0y42j
15 May 24
Quarterly report
4:19pm
10-Q
qav6ybtn7zs 87drn
15 May 24
Quarterly report
4:19pm
10-Q
eaz8t2
15 May 24
Quarterly report
4:19pm
10-Q
v8gwembj
15 May 24
Quarterly report
4:19pm
10-Q
wnz9em
15 May 24
Quarterly report
4:19pm